Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 trial of ibrutinib versus venetoclax + obinutuzumab versus ibrutinib + venetoclax in previously untreated CLL
2019-003854-99Phase 3Active
- Sponsor
- University of Cologne
- Start
- Oct 2020
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) comparing Ibrutinib monotherapy, Fixed-duration venetoclax + obinutuzumab and Fixed-duration ibrutinib + venetoclax (3 arms). Primary endpoint: Progression-free survival. Started Oct 2020; status: active.
02
Drugs
ibrutinibvenetoclaxobinutuzumab
03
Conditions
chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)
Beyond the preview
Go deeper on 2019-003854-99.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-003854-99.